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Flaviviruses transmitted by arthropods represent a tremendous disease burden for humans, causing millions
of infections annually. All vector-borne flaviviruses studied to date suppress host innate responses to infection
by inhibiting alpha/beta interferon (IFN-/)-mediated JAK-STAT signal transduction. The viral nonstruc-
tural protein NS5 of some flaviviruses functions as the major IFN antagonist, associated with inhibition of
IFN-dependent STAT1 phosphorylation (pY-STAT1) or with STAT2 degradation. West Nile virus (WNV)
infection prevents pY-STAT1 although a role for WNV NS5 in IFN antagonism has not been fully explored.
Here, we report that NS5 from the virulent NY99 strain of WNV prevented pY-STAT1 accumulation, sup-
pressed IFN-dependent gene expression, and rescued the growth of a highly IFN-sensitive virus (Newcastle
disease virus) in the presence of IFN, suggesting that this protein can function as an efficient IFN antagonist.
In contrast, NS5 from Kunjin virus (KUN), a naturally attenuated subtype of WNV, was a poor suppressor of
pY-STAT1. Mutation of a single residue in KUN NS5 to the analogous residue in WNV-NY99 NS5 (S653F)
rendered KUN NS5 an efficient inhibitor of pY-STAT1. Incorporation of this mutation into recombinant KUN
resulted in 30-fold greater inhibition of JAK-STAT signaling than with the wild-type virus and enhanced KUN
replication in the presence of IFN. Thus, a naturally occurring mutation is associated with the function of NS5
in IFN antagonism and may influence virulence of WNV field isolates.
The continued emergence and reemergence of flaviviruses
transmitted by mosquitoes and ticks is associated with signifi-
cant human morbidity and mortality worldwide. These viruses
include West Nile virus (WNV), Japanese encephalitis virus
(JEV), dengue virus (DENV), yellow fever virus (YFV), and
tick-borne encephalitis virus (TBEV). Despite their impor-
tance as human pathogens, no specific therapies exist for treat-
ment of infection with any of the flaviviruses. Host type I
interferon (IFN-/) responses are critical to recovery from
infection (27, 51, 54), and IFN-2a has been tested in human
clinical trials as a potential therapeutic for flavivirus infection.
However, such treatment has had limited success (48, 55). One
reason for ineffectiveness of IFN may be that flaviviruses can
suppress IFN-mediated signal transduction and thus dampen
the antiviral effects of IFN on infected cells (5). Indeed, in the
case of WNV and JEV, virus virulence correlates positively
with the ability to inhibit IFN-mediated signal transduction
(19, 22). Therefore, determining how flaviviruses suppress this
vital host response will facilitate the understanding of virus
virulence. Furthermore, this work will identify targets for the
development of therapeutics that, when administered with
IFN, potentiate its actions as an antiviral treatment.
Following cellular recognition of virus infection, IFN-/ is
secreted and binds in an autocrine and paracrine manner to
cell surface receptors, IFN- receptor subunits 1 and 2
(IFNAR1 and IFNAR2), to activate Janus kinase-signal
transducer and activator of transcription (JAK-STAT) signal
transduction (47). Briefly, IFN binding ligates the receptors,
which promotes trans- and auto-phosphorylation of JAKs
(Jak1 and Tyk2) associated with the receptor subunits (16).
The JAKs then phosphorylate the intracellular domains of the
receptors, creating a docking site for STAT1 and STAT2. The
STATs, in turn, are phosphorylated by the JAKs, inducing
heterodimerization of STAT1 and STAT2 and binding of a
third component, IFN-regulatory factor-9 (IRF-9), to form the
transcription factor IFN-stimulated gene factor 3 (ISGF3) (15,
47). ISGF3 then translocates to the nucleus, where it binds to
the IFN-stimulated response element (ISRE) in the promoter
region of IFN-stimulated genes (ISGs) (9), such as protein
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kinase R, the Mx proteins, 2,5-oligoadenylate synthetase, and
ISG15. ISG expression contributes to the cellular antiviral
state and modulates cell proliferation, cell death, and, depend-
ing on the cell type, immune responses to infection (18).
All flaviviruses examined thus far, including WNV (11), JEV
(24), Langat virus (LGTV; a member of the TBEV antigenic
complex) (6), and DENV (14), can suppress IFN-mediated
JAK-STAT signaling by inhibiting JAK phosphorylation. This
block prevents downstream signaling including tyrosine phos-
phorylation and nuclear localization of STAT1 and STAT2 as
well as ISG expression. DENV imposes an additional block to
signaling by reducing the cellular levels of STAT2 expression
(17). We previously identified the nonstructural protein NS5 of
LGTV as a potent antagonist of STAT1 phosphorylation and
downstream signaling (6). NS5 is approximately 900 amino
acids in length and is highly conserved between flaviviruses
owing to the fact that it encodes the viral methyltransferase
(MTase) and RNA-dependent RNA polymerase (RdRp). The
IFN antagonist domain of LGTV NS5 maps between amino
acids 355 and 735 and thus is contained within the RdRp
domain (44). Similarly, NS5 proteins from TBEV (59) and
JEV (23) antagonize STAT1 phosphorylation, most likely as a
result of suppression of JAK activation. Finally, NS5 from
DENV has recently been shown to contribute to IFN antag-
onism by binding and degrading STAT2 (2, 33). Hence, the
flavivirus NS5 protein appears critical to flavivirus resistance
to IFN.
Other flavivirus nonstructural proteins besides NS5 can con-
tribute to flavivirus IFN resistance. The flavivirus genome en-
codes one large polyprotein that is cleaved into three structural
proteins (core, membrane [derived from a precursor, desig-
nated prM], and the envelope protein [E]) and seven nonstruc-
tural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and
NS5) (25). Expression of the NS4B protein from DENV (se-
rotype 2) suppresses STAT1 phosphorylation in IFN-treated
cells (38). The ability of NS4B to prevent STAT1 activation
was dependent on the 23-amino-acid signal peptide derived
from the NS4A coding sequence (termed 2K for 2,000-molec-
ular-weight peptide) (37); its activity was augmented by the
addition of NS2A and NS4A (38). The NS4B proteins includ-
ing the 2K fragment (2KNS4B) from WNV and YFV were
similar to 2KNS4B of DENV-2 in their abilities to suppress
JAK-STAT signaling (37). Thus, 2KNS4B is thought to be the
primary antagonist of STAT1 phosphorylation encoded by
these three viruses. Additional studies have been performed
using Kunjin virus (KUN), an attenuated subtype of WNV
endemic to Australia that only rarely causes cases of clinical
disease in humans. This work demonstrated that multiple non-
structural proteins may contribute to antagonism of IFN sig-
naling, including NS2A, NS2B, NS3, NS4A, and NS4B. A role
for KUN NS5 in IFN antagonism was not detected in this study
(26).
Given the ability of JEV to utilize NS5 as an IFN antagonist
(23), we hypothesized that NS5 from WNV (which belongs to
the same antigenic complex as JEV) may also suppress IFN
responses. Furthermore, we reasoned that this activity may not
have been previously recognized using KUN NS5 if the relative
suppressive activity of IFN-antagonist proteins differs between
virulent and attenuated virus strains. To test these questions,
we used an NS5 expression construct corresponding to the
virulent NY99 strain of WNV (WNV-NY99) and examined its
effect on IFN--dependent JAK-STAT signaling. We also
compared the ability to suppress STAT1 phosphorylation of
2KNS4B and NS5 proteins derived from a number of flavi-
viruses from the TBEV and JEV antigenic complexes with
various degrees of virulence in humans. This work revealed
WNV-NY99 NS5 as a potent suppressor of IFN-mediated
JAK-STAT signaling while KUN NS5 was a poor inhibitor.
We found that a single residue in KUN NS5 at position 653
was associated with reduced IFN antagonism during virus
replication, suggesting that NS5 function in suppression of
IFN responses may influence virus virulence in humans.
Taken together, these studies begin to dissect potential
mechanisms of flavivirus resistance to IFN and thus have
direct implications for live attenuated vaccine design.
MATERIALS AND METHODS
Cells, virus, and transfection. HEK293T, HEK293, and Vero cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
fetal calf serum. Recombinant Newcastle disease virus expressing green fluores-
cent protein (NDV-GFP) was grown in 10-day-old embryonated chicken eggs as
previously described (45). All transfections were performed using Lipofectamine
2000 in OptiMEM (Invitrogen).
Generation of 2KNS4B and NS5 expression constructs. For use in the NDV-
GFP bioassay and ISRE activity assay, cDNA encoding DENV-2 core protein
and NS5 was derived from the full-length clone pD2/IC-30P (provided by R.
Kinney, National Center for Infectious Diseases, CO), and WNV NS5 was
derived by reverse transcription-PCR (RT-PCR) of RNA isolated from Vero
cells containing the WNV NY3356 replicon (53) (provided by P. Y. Shi, Novar-
tis). This WNV NS5 protein sequence is derived from WNV strain NY 2000-
crow3356 and is identical to the WNV-NY99 NS5 sequence. The genes were
cloned into the mammalian expression vector pCAGGS in frame with a C-
terminal hemagglutinin (HA) epitope tag. The pCAGGS-HA-Nipah virus (NiV)
V plasmid was a kind gift from M. Shaw (Mount Sinai School of Medicine, NY).
LGTV NS5 and 2KNS4B were derived following PCR amplification using the
LGTV E5 infectious cDNA clone as the template (kindly provided by A. Pletnev,
NIAID, NIH). TBEV (strain Hypr) and JEV-SA14-14-2 (JEV-SA) cDNAs for
NS proteins were obtained following RT-PCR of RNA isolated from virus-
infected cells. This work with TBEV was performed in biosafety level 4 facilities
at the University of Texas Medical Branch. KUN and WNV-NY99 NS protein
cDNAs were amplified by PCR from infectious molecular cDNA clones (20; also
W. Liu, V. Mokhonov, and A. Khromykh, unpublished data), whereas JEV
Nakayama (JEV-N) NS proteins were PCR amplified from replicon cDNA (P.
Mason, unpublished data). Primers for each amplification are detailed in
Table 1.
After PCR amplification, each gene was directionally cloned into Gateway
entry vectors (Invitrogen, Carlsbad, CA), followed by subcloning into
pcDNA6.2DEST/V5 (Invitrogen) to generate C-terminal V5 epitope-tagged
genes (Table 1). The sequence of each construct was verified by DNA sequenc-
ing.
Site-directed mutants of NS5 were made using a QuikChange Lightning site-
directed mutagenesis kit according to the manufacturer’s instructions (Strat-
agene) with the primers detailed in Table 2. Mutations were made in pENTR/
SD/D-TOPO entry vector, followed by sequencing and recombination into
pcDNA6.2DEST/V5.
NDV-GFP bioassay. Vero cells were transfected with either the empty
pCAGGS plasmid or plasmids encoding various viral proteins as detailed in
specific experiments. Expression of DENV-2 core protein was included as a
negative control for IFN antagonism, whereas the NiV V, DENV-2 NS5, and
LGTV NS5 proteins were included as positive controls. At 24 h posttransfection,
cells were treated with 1,000 U/ml of human IFN- (PBL). Following 24 h of
IFN- treatment, cells were infected with NDV-GFP as described previously
(45). Fluorescence images were obtained at 14 h postinfection (hpi).
Immunofluorescence. To examine virus protein expression and STAT1 phos-
phorylation in cells, Vero cells expressing each protein or infected with KUN
(multiplicity of infection [MOI] of 1) were treated with human IFN- for 15 min,
fixed in ice-cold 100% methanol for 10 min, and stained using anti-phosphoty-
rosine 701-STAT1 (Cell Signal Technologies) and either anti-V5 (Invitrogen)
antibodies as previously described (6) or a cocktail of monoclonal antibodies to
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WNV NS5 at a 1:20 dilution (13). Images were captured using a Zeiss Axio
Scope with Axiovision software or a Zeiss LSM710 confocal microscope.
Reporter gene assays. HEK293T cells were cotransfected with pCAGGS plas-
mids encoding various viral proteins, the IFN-inducible chloramphenicol acetyl-
transferase (CAT) reporter (ISRE54-CAT) plasmid, and a plasmid constitutively
expressing the firefly luciferase protein. The V5-tagged LGTV NS5 plasmid also
served as a positive control. At 24 h posttransfection, cells were treated with
1,000 U/ml IFN- for another 24 h prior to harvest and assay for CAT activity,
as previously described (46). pCAGGS-firefly luciferase and pISRE-54-CAT
reporter plasmids were kind gifts from L. Martinez-Sobrido (University of Roch-
ester, NY). Alternatively, HEK293 cells were cotransfected with plasmids en-
coding an IFN-inducible firefly luciferase reporter (pISRE-luc; Stratagene) and
the constitutive Renilla firefly expression plasmid, pRL-TK (Promega). At 24 h
posttransfection, the HEK293 cells were infected with wild-type (WT) KUN or
KUN NS5 carrying the mutation S653F ([NS5:S653F] MOI of 1). At 24 hpi, cells
were treated with 1,000 U/ml of human IFN-. Following 6 to 7 h of treatment
with IFN, cells were lysed and measured for luciferase activities according to the
manufacturer’s instructions (Promega). The reporter activity of the IFN-treated
sample was normalized to the constitutively expressed luciferase value of that
sample to control for transfection efficiency.
Flow cytometry. Vero cells transfected with the empty vector or various NS5
expression constructs were treated with 1,000 U/ml IFN- for 15 min, washed
twice in cold Dulbecco’s phosphate-buffered saline (DPBS), and trypsinized for
10 min at 37°C to dislodge cells. Cells were resuspended in freshly prepared 2%
paraformaldehyde–DPBS and incubated for 10 min at 37°C, followed by perme-
abilization in 90% methanol for 10 min on ice. Cells were washed once in stain
buffer (BD Pharmingen, San Diego, CA), followed by incubation with anti-
pY(701)-STAT1 conjugated to Alexa Fluor 647 (BD Pharmingen) and anti-V5
conjugated to fluorescein isothiocyanate (FITC; Invitrogen) for 45 min at room
temperature in the dark. Alexa Fluor 647- and FITC-conjugated mouse immu-
noglobulin G2a (IgG2a) were used as isotype controls. Cells were washed once
in stain buffer and analyzed using a FACSCalbur or FACSAria flow cytometer
(BD Biosciences) and FlowJo software (Tree Star). After V5-positive cells were
gated, the percent tyrosine-phosphorylated STAT1 (pY-STAT1) inhibition was
determined as the fraction of V5-positive cells that were pY-STAT1 negative.
Generation of recombinant KUN containing NS5 S653F. The NS5 S653F
mutation was generated using QuikChange PCR on an intermediate plasmid that
was constructed in two steps. First, a 1,958-bp region comprising the last 1,334
nucleotides of the NS5 gene and complete 3 untranslated region (UTR) was
amplified from the FLSDX 250pro plasmid (12, 20) using the following primer
pair: KUN NS5-HindIII, GGCAAGCTTGAGTTGTTGGACGGGGA (engi-
neered to contain a HindIII restriction site, indicated in bold); and KUN
XhoI-R, CCCCCTCGAGCAATTGT. The amplification product was cloned
into a pcDNA3 vector using HindIII and XhoI restriction sites. The HindIII and
XbaI fragment from pcDNA3-NS5 plasmid containing the area of interest was
then cloned into a pUC18 vector. QuikChange PCR was carried out on the
pUC18-NS5 plasmid with Pfu DNA polymerase using the 5 to 3 sense primer
GTTAGAACCTGGCTGTTCGAGAATGGGGAGGAA and antisense primer
TTCCTCCCCATTCTCGAACAGCCAGGTTCTAAC. The resulting mutated
fragment was then cloned back into the full-length FLSDX 250pro plasmid using
the SgrAI and XhoI restriction sites, and the S653F mutation was confirmed by
sequencing.
To produce infectious virus, in vitro transcription was carried out with SP6
polymerase using 1 g of XhoI-linearized plasmid as a template; the resulting
RNA transcript was electroporated into 5  106 BHK-21 cells. Virus recovered
following electroporation was used to infect Vero76 cells at an MOI of 0.1, and
the supernatant was collected at approximately 72 h postinfection, centrifuged at
low speed, and then aliquoted for storage at 80°C. Virus replication was
TABLE 1. Primer sequences used to PCR amplify viral genes
Virus
2KNS4B primer sequence NS5 primer sequence
5 Primera 3 Primer 5 Primera 3 Primer
LGTV CACCATGAGTAGTGATGA
CAACAAACTGGCATA
ACGCCGTGTCCCAGTGG
TCCGGAGCC
CACCATGGGTGGATCCG
AGGGAGAC
AAATATTGAGCTCTCCA
GTTTGAGCTC
TBEV CACCATGAGCAGTGACGA
CAACAAACTGGC
ACGCCTACCCCCAGAAG
CTCGAAGCC
CACCATGGGTGGTTCTG
AGGGAGAC
GATTATTGAGCTCTCCA
GTCTGAGCTC
WNV-NY99 CACCATGTCGCAGACAGA
CAACCAGCTAGC
TCTTTTTAGTCCTGGTTT
TTCCATG
CACCATGGGTGGGGCA
AAAGGACGC
CAGTACTGTGTCCTCAA
CCAAAGTTG
KUN CACCATGTCGCAGACAGA
CAACCAGCTAGC
TCTCTTCAGCCCTGGTTT
TTCCATG
CACCATGTCGCAGACAG
ACAACCAGCTAGC
CAATACTGTATCCTCAA
CCAATG
JEV-Nakayama CACCATGTCACAGACAGA
TAACCAACTGGC
CCTTTTCAAGGAGGGCT
TGTCAGCG
CACCATGGGAAGGCCT
GGGGGCAGG
GATGACCCTGTCTTCCT
GGATC
JEV-SA14142 CACCATGTCACAGACAGA
TAACCAACTGGC
CCTTTTCAAGGAGGGCT
TATCAGCG
CACCATGGGAAGGCCT
GGGGGCAGG
GATGACCCTGTCTTCCT
GGATCAAGAC
a Bases in italics were added to the 5 primers to insert start codons and enable cloning into the TOPO Gateway system (Invitrogen).
TABLE 2. Primer sequences used to mutate WNV-NY99 or KUN NS5 expression constructs
Primer name Sense primer sequence (5 to 3) Antisense primer sequence (5 to 3)
NY99 N377A GAGTGAAGTACGTGCTCGCCGAGACCACCAAC
TGGT
ACCAGTTGGTGGTCTCGGCGAGCACGTACTTC
ACTC
NY99 N381A GCTCAACGAGACCACCGCCTGGTTGTGGGCGTTT AAACGCCCACAACCAGGCGGTGGTCTCGTTGAGC
NY99 E627A CTGGTGAGGATGATGGCAGGGGAAGGAGTGATT AATCACTCCTTCCCCTGCCATCATCCTCACCAG
NY99 E629A GGATGATGGAAGGGGCAGGAGTGATTGGCCC GGGCCAATCACTCCTGCCCCTTCCATCATCC
NY99 VI631/632AA GATGGAAGGGGAAGGAGCGGCTGGCCCAGATG
ATGTGG
CCACATCATCTGGGCCAGCCGCTCCTTCCCCTTC
CATC
NY99 W651A GACCCAAAGTCAGGACCGCGCTGTTTGAGAAT
GGGG
CCCCATTCTCAAACAGCGCGGTCCTGACTTTG
GGTC
NY99 F653S CAAAGTCAGGACCTGGCTGTCTGAGAATGGG
GAAG
CTTCCCCATTCTCAGACAGCCAGGTCCTGACTTTG
NY99 E378A AAGTACGTGCTCAACGCGACCACCAACTGGTTG CAACCAGTTGGTGGTCGCGTTGAGCACGTACTT
NY99 W382A TCAACGAGACCACCAACGCGTTGTGGGCGTTT
TTGG
CCAAAAACGCCCACAACGCGTTGGTGGTCTCG
TTGA
KUN S653F CCCAAGGTTAGAACCTGGCTGTTTGAGAATG
GGGA
TCCCCATTCTCAAACAGCCAGGTTCTAACCTTGGG
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quantified by a focus-forming assay as previously described (36) using a cocktail
of monoclonal antibodies to NS5 (13) diluted 1:50.
Western blot analysis. Cells were lysed in radioimmunoprecipitation assay
(RIPA) buffer (1 mM EDTA, 50 mM Tris, 150 mM NaCl, 0.5% deoxycholate
[DOC], 0.1% SDS, 1% NP-40) and centrifuged at 200  g for 10 min at 4°C.
Protein in the cleared lysate was quantified using a Bradford protein assay
(Bio-Rad Laboratories, Hercules, CA) and subjected to SDS-PAGE, followed by
transfer to nitrocellulose membranes. Membranes were blocked and probed for
V5, STAT1, pY-STAT1, or actin as previously described (6, 44). Alternatively,
membranes were probed with anti-HA (Sigma), a mouse anti-WNV E polyclonal
(kind gift of R. Tesh, University of Texas Medical Branch, TX), or a cocktail of
monoclonal antibodies to WNV NS5 at 1:500 (13).
Structural modeling. To determine amino acids that may be important to
WNV NS5 function, the NS5 sequences from LGTV, WNV-NY99, and KUN
were aligned using Clustal W alignment within DNAStar Lasergene software.
Residues of interest were modeled on the KUN NS5 RdRP structure (Protein
Data Bank code 2HFZ) (31) using PyMol.
Statistical analysis. Data from ISRE reporter assays and flow cytometry using
IFN- at 1,000 U/ml were analyzed by one-way analysis of variance (ANOVA)
with either Dunnett’s multiple comparison test or Tukey’s posttest to determine
significant differences (P  0.05) between individual groups. Virus titration data
were analyzed by a two-tailed t test or Mann-Whitney U test as indicated in the
figure legends.
RESULTS
Identification of WNV-NY99 NS5 as an IFN antagonist. The
NS5 proteins from LGTV, TBEV, JEV, and DENV disrupt
IFN-mediated JAK-STAT signaling, albeit through varied
mechanisms (2, 6, 23, 59). It is well established that WNV
antagonizes IFN-mediated signal transduction (11, 26) al-
though the contribution of NS5 to this is not fully resolved. To
examine the contribution of WNV-NY99 NS5 to IFN antago-
nism, we first analyzed its impact on replication of NDV-GFP
in the presence of IFN. NDV-GFP is highly sensitive to the
antiviral effects of IFN. Thus, stimulation of cells with IFN
prior to infection prevents NDV-GFP replication, as demon-
strated by a lack of GFP expression. NDV-GFP replication can
be rescued by expressing antagonists of IFN signaling such as
the NiV V protein in cells prior to infection (45, 52). Vero cells
were transfected with an empty plasmid or plasmids expressing
DENV-2 core (negative control), NiV V, DENV-2 NS5,
LGTV NS5 (as positive controls), or WNV-NY99 NS5 and
treated with IFN-. Twenty-four hours after IFN treatment,
cells were infected with NDV-GFP and examined at 14 hpi for
GFP expression (Fig. 1A). NDV-GFP replication was not de-
tected in cells transfected with an empty plasmid or in those
expressing the DENV-2 core protein. However, the presence
of the NiV V protein, DENV-2 NS5, LGTV NS5, or WNV
NS5 facilitated NDV-GFP replication (Fig. 1A). By immuno-
fluorescence staining, NDV-GFP was present only in cells ex-
pressing the flavivirus NS5 proteins (Fig. 1B). These results
indicate that NS5 from WNV-NY99 can function as a suppres-
sor of host IFN responses.
We next wanted to determine if WNV NS5 specifically in-
hibits JAK-STAT signaling in response to IFN. Thus, we ex-
amined ISRE promoter activation in HEK293T cells express-
ing NS5 from WNV-NY99, DENV-2, or LGTV. Expression of
DENV-2 core or NiV V proteins was again included as a
negative and positive control, respectively. The expression of
each protein is shown in Fig. 1C. Plasmids encoding the dif-
ferent virus proteins were cotransfected with the reporter plas-
mid pISRE-54-CAT as well as a plasmid driving the constitu-
tive expression of firefly luciferase. After a 24-h treatment with
IFN-, cell lysates were harvested and assayed for CAT and
luciferase activities (Fig. 1D). IFN treatment of cells trans-
fected with the empty vector or expressing DENV-2 core pro-
tein resulted in a significant increase in CAT activity (P 
0.05), demonstrating activation of JAK-STAT signaling. How-
ever, CAT activity in IFN-treated cells expressing NiV V,
DENV-2 NS5, WNV-NY99 NS5, or LGTV NS5 was not sta-
tistically different from activity in cells transfected with an
empty plasmid and not treated with IFN (Fig. 1D), suggesting
that JAK-STAT signaling was not active in these cultures.
Thus, WNV-NY99 NS5 suppresses IFN responses specifically
by interfering with JAK-STAT signaling, similar to NS5 from
LGTV or DENV-2.
Comparison of NS5 and 2KNS4B function in inhibition of
pY-STAT1. In cells infected with WNV, JEV, or LGTV, sup-
pression of signaling is associated with the failure of both
STAT1 and STAT2 to be phosphorylated on tyrosine residues
(6, 11, 24, 26). In turn, this prevents STAT nuclear transloca-
tion and ISRE-driven gene expression. The 2KNS4B protein
from WNV has been demonstrated to prevent STAT1 phos-
phorylation in IFN-treated cells (26, 37). To compare the im-
pact of NS5 and 2KNS4B from virulent and attenuated strains
of these viruses on STAT1 activation, we examined phosphor-
ylation and nuclear localization of STAT1 (pY-STAT1) by
immunofluorescence assay (IFA) in IFN-treated cells express-
ing NS5 or 2KNS4B derived from WNV-NY99 and KUN or
the virulent JEV Nakayama strain (JEV-N) (8, 39) and the live
attenuated vaccine strain, JEV-SA14-14-2 (JEV-SA) (40, 42)
(Fig. 2).
In Vero cells transfected with the empty expression plasmid
(pcDNA6.2/V5) and treated with IFN-, pY-STAT1 was
readily detected in the nucleus of the vast majority of cells
(data not shown). However, the majority of cells expressing
NS5 from WNV-NY99 or JEV-N and treated with IFN- were
negative for pY-STAT1 (Fig. 2). This was similar to results
obtained with LGTV or TBEV NS5 (6; also data not shown).
In contrast, nuclear pY-STAT1 was detectable in numerous
cells expressing low levels of NS5 from KUN or in JEV-SA
NS5-expressing cells (Fig. 2, arrowheads). Phosphorylated
STAT1 was observed in the nucleus of cells expressing
2KNS4B from all viruses tested (Fig. 2). These observations
suggest that NS5 from WNV-NY99 prevents the phosphoryla-
tion and nuclear translocation of STAT1 in response to IFN-
and, hence, support results obtained using the NDV comple-
mentation and ISRE activity assays. As expected (23), NS5
derived from virulent JEV-N also efficiently prevented pY-
STAT1 accumulation.
To quantify the intrinsic ability of each 2KNS4B and NS5
protein to impede JAK-STAT signaling, we used flow cytom-
etry to measure pY-STAT1 in cells expressing V5 epitope-
tagged 2KNS4B or NS5. This quantitative technique to mea-
sure pY-STAT1 provides advantages over other measurements
because the transfection efficiency between samples can be
directly normalized by gating V5-positive cells (44). Vero cells
transiently expressing each V5 fusion protein (expression lev-
els are shown in Fig. 3A) were stimulated with IFN-, fixed,
permeabilized, and incubated with pY-STAT1- and V5-specific
antibodies. During analysis, the V5-positive cell population
was gated, and the percent inhibition of pY-STAT1 for each
protein was defined as the proportion of V5-expressing cells
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that were pY-STAT1 negative (Fig. 3B). NS5 and 2KNS4B
from LGTV were used as positive and negative controls for
pY-STAT1 inhibition, respectively.
NS5 from WNV-NY99 was an efficient antagonist of signal-
ing, with approximately 85% of NS5-positive cells negative for
pY-STAT1 (Fig. 3C). This level of inhibition was significantly
greater than that of the WNV-NY99 2KNS4B protein. In con-
trast, KUN NS5 suppressed pY-STAT1 in significantly fewer
cells (in approximately 42% of NS5-positive cells) than WNV-
NY99 NS5 (Fig. 3C). This level of inhibition by KUN NS5 was
similar to that produced by the KUN 2KNS4B protein. Taken
together, these results suggest that NS5 derived from the vir-
ulent WNV-NY99 is the most potent antagonist of IFN-medi-
ated JAK-STAT signaling encoded by this virus. Furthermore,
the results suggest that KUN NS5 is an inefficient IFN antag-
onist.
As also shown in Fig. 3C, NS5 derived from the virulent
JEV-N strain was an efficient suppressor of signal transduction,
with approximately 90% of IFN--treated cells negative for
pY-STAT1. Expression of JEV-N 2KNS4B also resulted in a
pronounced level of suppression, at about 65%. Interestingly,
suppression of pY-STAT1 by JEV-SA NS5 was significantly
FIG. 1. WNV NS5 antagonizes host IFN- responses by inhibiting JAK-STAT signaling. (A) Effect of WNV NS5 expression on NDV-GFP
replication in the presence of IFN. Vero cells transfected with an empty plasmid or a plasmid expressing individual virus proteins as indicated were
treated with 1,000 U/ml IFN- for 24 h and then infected with NDV-GFP. NDV-GFP replication was monitored by GFP fluorescence at 14 hpi.
(B) Examples from panel A demonstrating NDV-GFP replication (green) in cells expressing flavivirus NS5 proteins (red). Nuclei are counter
stained with 4,6-diamidino-2-phenylindole (DAPI; blue). (C) Western blot demonstrating the relative expression of each viral protein in
HEK293T cells. (D) Effect of WNV NS5 on ISRE-dependent gene expression. HEK293T cells were transfected with the ISRE-CAT reporter
plasmid, a plasmid constitutively expressing firefly luciferase, and either an empty plasmid or a plasmid expressing the virus protein indicated and
treated with IFN for 24 h. CAT activity in cell lysates was determined and normalized to the luciferase activity in each sample. Fold induction of
CAT activity was determined relative to the normalized CAT activity value of cells transfected with the empty vector and not treated with IFN.
Error bars indicate standard errors of the mean (SEM) from three individual experiments performed in triplicate; asterisks indicate significant
differences from cells transfected with the empty vector and not treated with IFN (P  0.05, by ANOVA followed by Dunnett’s multiple
comparison test).
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lower than that by JEV-N NS5 and not different from that by
JEV-N 2KNS4B. There was no significant difference between
the relative abilities of the 2KNS4B proteins from the two JEV
strains to inhibit signaling. Consistent with previously pub-
lished work (23), these results suggest that NS5 derived from
JEV is a more efficient antagonist of IFN-mediated JAK-
STAT signaling than 2KNS4B but that JEV 2KNS4B likely
contributes to suppression of this signaling pathway in infected
cells. These results also indicate that NS5 from the live atten-
uated vaccine strain is a less efficient antagonist than NS5 from
virulent JEV strains.
Finally, expression of NS5 and 2KNS4B from TBEV-Hypr
resulted in approximately 90% and 15% inhibition of pY-
STAT1, respectively (Fig. 3C). These levels of inhibition were
not statistically different from their LGTV-derived counter-
parts. The finding that TBEV NS5 is an efficient antagonist of
IFN-mediated signaling is consistent with the recent findings of
Werme et al. (59).
Identification of residues important for WNV NS5 function
as an IFN antagonist. We previously identified a number of
amino acids within LGTV NS5 required for its IFN antagonist
function (44). The residues identified were positioned in two
noncontiguous areas of the protein, between amino acids 374
to 380 and 624 to 647, that mapped proximal to each other
when modeled onto the KUN RdRp crystal structure (31, 44).
To determine if the specific residues identified for LGTV NS5
were also important for WNV-NY99 NS5 function, we initially
made site-to-alanine mutations at the analogous residues in
WNV-NY99 NS5 (N377, N381, E627, E629, VI631/632, and
W651) (Fig. 4A) and examined the resulting degree of sup-
pression using flow cytometry. The mutations did not appear to
affect NS5 expression levels (Fig. 4B). Mutation at VI631/
632AA and W651A significantly decreased the ability of WNV-
NY99 NS5 to suppress IFN signaling, with W651A reducing
the activity of NS5 by approximately 45% (Fig. 4C). By IFA,
cells expressing NY99 NS5:W651A showed predominantly nu-
clear accumulation of pY-STAT1, suggesting that this protein
had reduced capacity to inhibit JAK-STAT signaling (Fig. 4D).
The mutations E627A and E629A did not affect WNV-NY99
NS5 antagonist function (Fig. 4C). Furthermore, the mutations
N377A and N381A did not affect NS5 function, but unlike
their counterparts in LGTV NS5, these WT residues have no
charge. We reasoned that the two residues adjacent to these
may have a more pronounced role due to their charge (E376)
or aromatic side chain (W382). Mutation at W382A had a
modest but significant effect on NY99 NS5-mediated suppres-
sion of IFN signaling, while E376A had no effect (Fig. 4C).
Thus, WNV NS5 residues W382, VI631/632, and W651 are
important to its function as an IFN antagonist.
As demonstrated in the experiment shown in Fig. 3C, NS5
derived from WNV-NY99 suppressed pY-STAT1 accumula-
tion better than KUN NS5. There are 10 amino acid differ-
ences between these two NS5 proteins, of which 9 represent
relatively conserved substitutions (Table 3). However, the mu-
tation at residue 653 from Phe (NY99) to Ser (KUN) repre-
sents a change in hydrophobicity and maps within the IFN-
antagonist domain identified for LGTV NS5 (Fig. 4A). To
determine if this residue is responsible for the different levels
of inhibition, we made an S653F mutation in KUN NS5 as well
as the converse mutation (F653S) in WNV-NY99 NS5 and
tested the ability of the mutant NS5 proteins to suppress pY-
STAT1 by flow cytometry. KUN NS5:S653F yielded a flow
cytometry profile that was more similar to that of WT NY99
NS5 (Fig. 5A), suppressing pY-STAT1 in approximately 76%
FIG. 2. Immunofluorescence of STAT1 phosphorylation and nu-
clear localization in cells expressing flavivirus NS5 and 2KNS4B pro-
teins. Vero cells were transfected with plasmids encoding the NS5 or
2KNS4B proteins derived from the indicated viruses, with each fused
to a C-terminal V5 epitope tag. At 24 h posttransfection, cells were
treated with IFN- for 15 min, fixed in methanol, and stained for
anti-V5 (red) and anti-pY-STAT1 (green). Arrowheads indicate ex-
amples of NS5-positive cells that are also positive for pY-STAT1.
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of cells, a result not significantly different from WT NY99 NS5
(Fig. 5B). The reverse mutation, F653S in WNV-NY99 NS5,
reduced the ability of this molecule to inhibit signaling to levels
similar to inhibition by WT KUN NS5 (Fig. 5B). Thus, the
residue at position 653 is a critical determinant of WNV NS5
antagonist function.
WNV NS5 residue S653F has an important role in IFN
antagonism during virus replication. To determine if the NS5
residue at position 653 has relevance to IFN antagonism in the
context of virus replication, the NS5:S653F mutation was in-
troduced into KUN using reverse genetics. WT KUN had a
small replication advantage in Vero cells but only at 96 hpi
(Fig. 6A). WT and NS5:S653F KUN viruses replicated equally
well in HEK293 cells (Fig. 6B). Taken together, these results
suggest that mutation at NS5:S653F did not drastically com-
promise the ability of KUN to replicate, despite the fact that
this mutation resides in the RdRP domain.
We first assessed the effect of the S653F mutation on IFN
antagonism using IFA. Vero cells were infected with WT and
mutant KUN for 48 h and then left untreated or treated with
1,000 U/ml IFN- for 15 min. The cells were then stained for
NS5 and pY-STAT1. Although the majority of cells infected
with WT KUN and treated with IFN were negative for pY-
STAT1, a substantial number of infected cells contained nu-
clear pY-STAT1 (Fig. 7). In contrast, pY-STAT1 was not ob-
served in IFN-treated cells infected with KUN NS5:S653F
(Fig. 7).
The ability of WT and mutant viruses to suppress pY-
STAT1 was also compared by Western blot analysis (Fig. 8A).
Phosphorylated STAT1 was readily detected in uninfected
HEK293 cells treated with 1,000 U/ml IFN-. Suppression of
pY-STAT1 in WT KUN-infected cells was evident at 48 hpi. In
contrast, KUN NS5:S653F replication was associated with an
almost complete lack of pY-STAT1 in IFN-treated cells at 24
hpi. Even though the two viruses grew equally well in HEK293
cells (Fig. 6B), the expression of NS5 and E proteins in KUN
NS5:S653F-infected cells was higher at 24 hpi, and NS5 ex-
pression tended to be higher at 72 hpi. We also observed
higher NS5 expression at 12 and 24 hpi in KUN NS5:S653F-
infected Vero cells (data not shown). These results support the
IFA results and demonstrate that the presence of S653F results
in more robust suppression of IFN-mediated JAK-STAT sig-
naling.
To quantify inhibition of signaling by WT and KUN NS5:
S653F viruses, we examined ISRE promoter activation in
HEK293 cells treated with IFN at 24 hpi. WT KUN replication
resulted in a 5.8-fold reduction in ISRE activity compared to
uninfected cells, whereas infection with KUN NS5:S653F re-
sulted in a 175-fold reduction. Thus, the presence of the 653F
FIG. 3. Quantification of inhibition of STAT1 phosphorylation by
flavivirus NS5 and 2KNS4B proteins. (A) Western blot demonstrating
the expression of NS5 and 2KNS4B proteins, each in frame with a
C-terminal V5 epitope tag, in Vero cells. (B) Flow cytometry analysis
to determine the percent inhibition of pY-STAT1 in Vero cells ex-
pressing flavivirus nonstructural proteins. Vero cells were fixed, per-
meabilized, and stained using antibodies that recognize pY(701)-
STAT1 and V5. The examples shown are cells transfected with an
empty plasmid and either untreated or treated with IFN- (top panels)
or cells expressing LGTV NS5 or WNV-NY99 NS5 and treated with
IFN- (lower panels). (C) Quantification of pY-STAT1 inhibition by
each protein analyzed by flow cytometry. V5-positive cells were gated
and examined for pY-STAT1. The percent pY-STAT1 inhibition is the
percentage of V5-positive cells (contained in quadrant 2 [Q2] and Q4
in B) that were pY-STAT1 negative (in Q4). The average level of
V5-negative cells that are also pY-STAT1 negative in IFN--treated
cultures (cells present in Q3) is illustrated by the dotted line as an
indication of the background levels in this assay. Error bars indicate
SEM from four independent experiments; asterisks indicate significant
differences (P  0.05, by ANOVA followed by Tukey’s test).
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mutation in NS5 resulted in a 30-fold greater inhibition of
IFN-dependent signaling than the presence of WT residue in
the context of virus replication.
Finally, we examined virus replication in the presence of
IFN. Vero cells were infected at an MOI of 0.001 and treated
with high-dose IFN- (100 to 1,000 U/ml) at 12 hpi. Infectious
virus in supernatants was measured at the times indicated in
the legend to Fig. 8C by focus-forming assay. In the presence
FIG. 4. Identification of residues important for WNV NS5 function as an IFN antagonist. (A) Position of residues selected for mutation
on the WNV KUN RdRp structure (31). The entire RdRp is shown on the left; the region of interest in IFN antagonism is shown on the
right. The residues demonstrated in this study to have a role in WNV-NY99 NS5 function in IFN antagonism are depicted in red (W382,
VI631/632, and W651) or green (residue 653), whereas those that were mutated to alanine with no effect on NS5 function are depicted in
blue. (B) Western blot demonstrating the relative expression of each WNV-NY99 or KUN NS5 mutant used in these studies. (C) Quan-
tification of pY-STAT1 inhibition by WNV-NY99 NS5 site mutants analyzed by flow cytometry. Error bars indicate SEM; asterisks indicate
significant differences from WT NY99 NS5 (P  0.05, by ANOVA followed by Dunnett’s test). (D) IFA of WNV-NY99 NS5 containing a
W651A mutation in IFN--treated Vero cells. NS5 is shown in red, and pY-STAT1 is shown in green.
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of IFN, replication of KUN NS5:S653F was significantly
greater than that of WT KUN at 72 and 96 hpi (Fig. 8C). Thus,
the S653F mutation in NS5 confers greater resistance to the
antiviral effects of IFN.
DISCUSSION
A major mechanism by which WNV evades the host antiviral
response is to suppress IFN-stimulated JAK-STAT signaling
(11, 19). In this report, we have demonstrated that NS5 from
the virulent NY99 strain of WNV is a potent inhibitor of
IFN-mediated signal transduction. WNV NS5 expression pre-
vented the development of the cellular antiviral state, as dem-
onstrated by its ability to augment NDV-GFP replication in
IFN-treated cells (Fig. 1A). As observed during infection (11,
19), IFN antagonism mediated by WNV-NY99 NS5 was asso-
ciated with failure of STAT1 to be phosphorylated (Fig. 3),
translocate to the nucleus (Fig. 2), and participate in the ex-
pression of ISRE-dependent genes (Fig. 1D). This work adds
WNV-NY99 to the number of highly pathogenic flaviviruses
that utilize NS5 as an efficient IFN antagonist (including
TBEV, DENV, and JEV), suggesting that this function of NS5
is essential to the success of flaviviruses as emerging and re-
emerging pathogens (28).
Effective host IFN responses are critical to recovery from
flavivirus infection. Thus, the relative ability of these viruses to
subvert the IFN response may be a decisive factor in their
virulence. In support of this concept, we found that NS5 from
WNV-NY99 was a potent suppressor of IFN responses,
whereas NS5 from the closely related but attenuated KUN was
not (Fig. 3). These results are consistent with previous work
that examined the ability of individual KUN proteins to sup-
press ISRE-dependent responses and did not find a role for
NS5 (26). A single residue at position 653 is largely responsible
for this difference since its mutation in KUN NS5 to the cor-
responding NY99 residue (S653F) conferred an ability to
antagonize signaling similar to that of WT NY99 NS5 (Fig.
5B). Furthermore, introduction of F653S to NY99 NS5 com-
promised the ability of this protein to prevent pY-STAT1
accumulation, suggesting that this residue is more generally
important for WNV NS5 function in IFN antagonism. Incor-
poration of the NS5 mutation S653F into a recombinant KUN
increased the virus’s ability to suppress IFN--mediated
STAT1 phosphorylation and ISRE-dependent gene expres-
sion. Strikingly, KUN NS5 bearing the S653F mutation during
transient expression demonstrated only a 2-fold increase in its
ability to inhibit pY-STAT1, yet replication of a recombinant
KUN bearing this mutation resulted in a 30-fold increase in
inhibition of signaling compared to WT virus (Fig. 8B). This
more potent antagonism was associated with greater resistance to
the antiviral effects of IFN during WNV replication (Fig. 8C). The
importance of S653F during virus replication provides definitive
evidence for the biological relevance of NS5 and, specifically, the
residue at position 653, in IFN antagonism.
Interestingly, we found that viral proteins accumulated to
higher levels at 24 hpi in KUN NS5:S653F-infected cells than
in cells infected with WT virus (Fig. 8A) without an increase in
FIG. 5. Residue 653 is largely responsible for the differences be-
tween NY99 and KUN NS5 function in IFN antagonism. (A) Flow
cytometry to determine the percent inhibition of pY-STAT1 in IFN-
-treated Vero cells expressing KUN and WNV-NY99 mutants. The
examples shown are cells expressing WT KUN NS5, KUN NS5:S653F,
WT WNV-NY99, and NY99 NS5:F653S. (B) Quantification of pY-
STAT1 inhibition by WNV-NY99 and KUN NS5 mutants by flow
cytometry. LGTV NS5 was included as a positive control for pY-
STAT1 inhibition. Error bars indicate SEM from four independent
experiments; asterisks indicate significant differences (P  0.05, by
ANOVA followed by Tukey’s test).
FIG. 6. Replication of WT KUN and KUN NS5:S653F in cell cul-
ture. Supernatants from Vero cells infected at an MOI of 0.001 (A) or
HEK293 cells infected at an MOI of 0.1 (B) were assayed for infectious
virus by focus-forming assay at the times indicated. Error bars indicate
SEM from three independent experiments performed in triplicate; the
asterisk indicates significant difference (P  0.05, Student’s t test).
FFU, focus-forming units.
TABLE 3. Differences in NS5 amino acid sequences between WNV
strain NY99 and WNV subtype KUN
Virus
NS5 amino acid residue at position:
25 33 162 177 247 312 531 653 731 877
NY99 T I I R R D K F V A
KUN I T L K K E R S T S
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infectious virus (Fig. 6). Because E and NS5 protein levels
were greater in both IFN-competent and -incompetent cells
infected with KUN NS5:S653F at 24 hpi, it is possible that the
S653F mutation not only increases resistance to IFN (Fig. 5B)
but also stabilizes NS5 expression. This may also result in a
general acceleration of protein expression (and perhaps RNA
replication) by stabilizing the replication complex. Incorpora-
tion of S653F into KUN NS5 expressed ectopically did not
alter its expression level (Fig. 4B). However, NS5 turnover is
likely to be more complex during virus replication, as exempli-
fied by the fact that DEN NS5-mediated degradation of
STAT2 was observed only when NS5 was expressed as part of
a cleavable polyprotein (2). Thus, the mutation may affect NS5
stability only after cleavage. Alternatively, NS5 may be stabi-
lized through increased binding to a cellular target induced
during virus replication. Future experiments will more pre-
cisely address the mechanism of IFN antagonism and its rela-
tionship to WNV NS5 turnover.
Residue 653 lies within not only the IFN antagonism domain
previously identified for LGTV NS5 but also the three-dimen-
sional pocket we previously proposed to mediate much of
LGTV NS5’s function in IFN resistance (44). In addition,
mutagenesis studies demonstrated that at least three WNV
NS5 residues located in this site, W382, VI631/632, and W651,
were important for IFN antagonism. Hence, this site appears
more broadly important to NS5 function, suggesting that the
mechanism of STAT1 inhibition, at least in part, may be com-
mon to NS5 proteins from both TBEV and JEV serogroups.
NS5 proteins from JEV-N and JEV-SA also demonstrated
significantly different abilities to prevent pY-STAT1 accumu-
lation (Fig. 3) and differ from each other at eight amino acids.
Based on the experiments presented here, we predict that
residue 640 within JEV NS5, located within the same site of
NS5 and divergent between JEV-N and JEV-SA strains, is
responsible for these differences. However, although LGTV
NS5 residues 355 to 735 are sufficient to inhibit IFN signaling
equally as well as the full-length protein, the analogous trun-
cation of WNV-NY99 or TBEV NS5 did not function effi-
ciently as antagonists (data not shown). While we did not finely
map the antagonism domains in these two proteins, only ex-
pression constructs corresponding to residues 1 to 735 retained
resistance to IFN in both cases. This is consistent with previous
FIG. 7. Immunofluorescence of pY-STAT1 in WT and NS5:S653F KUN-infected cells. Vero cells were infected with WT or NS5:S653F KUN
and treated with 1,000 U/ml IFN- at 48 hpi, followed by staining for NS5 (red) and anti-pY-STAT1 (green). Nuclei were counterstained with
DAPI.
3512 LAURENT-ROLLE ET AL. J. VIROL.
mapping studies of JEV NS5 (23) and with the requirement for
sequences in the MTase domain of TBEV NS5 for optimal
inhibition (59). Thus, additional features of some NS5 mole-
cules may also contribute to suppression.
The relationship between NS5 function and virulence of the
corresponding virus was not observed for the tick-borne flavi-
viruses. NS5 from attenuated LGTV and pathogenic TBEV
both exhibited the same high degree of pY-STAT1 suppression
(Fig. 3C). Of course, flaviviruses encode factors other than
NS5 that contribute to pathogenicity. The E protein, for ex-
ample, is particularly important in flavivirus virulence since it
mediates virus binding to cellular receptors and entry to the
host cell (reviewed in reference 32). The presence of specific
glycosylation sites in E is associated with WNV virulence (3, 4),
and the WNV E protein can suppress innate immune re-
sponses to double-stranded RNA, a phenomenon dependent
on E glycosylation status (1). The E protein has recently been
demonstrated to affect sensitivity of JEV to host IFN responses
since a mutation in E that reduced replication efficiency also
reduced the capacity to antagonize IFN-mediated JAK-STAT
signaling (22). Hence, while NS5 function in IFN resistance is
likely required for virus replication and pathogenesis, it is not
the only candidate for defining flavivirus virulence.
The accumulated data presented here and previously (2, 6,
23, 44, 59) suggest that NS5 is the most potent of the flavivirus-
encoded IFN antagonists in mammalian cells. However, NS4B
also antagonizes responses, a function that is dependent on the
2K signal sequence derived from NS4A, and is enhanced in the
presence of the other small hydrophobic NS proteins, NS2A
and NS4A (37, 38). During flavivirus replication, these three
proteins are involved in endoplasmic reticulum membrane pro-
liferation, membrane anchoring of the viral replication com-
plex, and RNA replication (28, 29, 34, 35, 50, 58). In the case
of WNV and probably all flaviviruses, membrane rearrange-
ment is concomitant with redistribution of cellular cholesterol
to sites of viral replication (30). The resulting loss of choles-
terol-rich lipid rafts in the plasma membrane is associated with
reduced IFN-mediated JAK-STAT signal transduction (30).
Thus, it is highly possible that the functions of NS4A, NS4B,
and the intervening 2K signal sequence in membrane rear-
rangement contribute to their IFN antagonism. However, this
does not readily explain why 2KNS4B from JEV can suppress
STAT1 phosphorylation at levels far greater than other
2KNS4B molecules, for example, from TBEV (Fig. 3C), unless
their roles differ in membrane alteration and potentially cho-
lesterol metabolism, which seems unlikely. Thus, a more spe-
cific mechanism of NS4B-mediated IFN antagonism may exist.
The use of multiple proteins to suppress IFN-mediated
FIG. 8. Replication of NS5:S653F KUN is associated with greater IFN resistance than WT KUN. (A) Western blot demonstrating increased
efficiency of IFN antagonism by KUN NS5:S653F. HEK293 cells were left uninfected or were infected with WT or NS5:S653F KUN at an MOI
of 1. At the times indicated, cells were treated with 1,000 U/ml of IFN- for 15 min, and cell lysates were analyzed for virus protein expression
(NS5 and E) and STAT1 phosphorylation. (B) Effect of S653F mutation on ISRE-dependent gene expression during KUN replication. HEK293
cells were transfected with the pISRE-luc reporter plasmid and a plasmid constitutively expressing Renilla luciferase. Cells were infected 24 h later
with WT or NS5:S653F KUN at an MOI of 1 and incubated for a further 24 h. Cells were treated with 1,000 U of IFN- for 7 to 8 h prior to assaying
for dual luciferase activities. Fold induction of firefly luciferase activity was determined relative to the normalized luciferase activity value of
virus-infected cells not treated with IFN. Error bars indicate SEM from three individual experiments; asterisks indicate significant differences from
cells transfected with the empty vector and not treated with IFN (P 0.005, by Student’s t test). (C) KUN replication in the presence of IFN. Vero
cells were infected with WT or NS5:S653F KUN at an MOI of 0.001 and treated with high-dose IFN- at 12 hpi. Supernatants were assayed for
infectious virus by focus-forming assay at the times indicated. Error bars indicate SEM from five independent experiments performed in triplicate;
an asterisk indicates significant difference (P  0.0079, Mann-Whitney test). FFU, focus forming units.
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JAK-STAT signaling, as well as using one relatively conserved
protein to target this pathway using different mechanisms, is
not unique to the flaviviruses. The best described examples of
this are the paramyxoviruses, a large family of negative-
stranded RNA viruses that includes several important human
pathogens such as measles virus, mumps virus, and NiV. The
V protein from mumps virus targets both STAT1 and STAT3
for proteasomal degradation (41, 57) whereas the simian virus
5 V protein degrades only STAT1 (10, 56), and the type II
human parainfluenza virus V protein degrades only STAT2
(43, 56). The NiV P gene encodes four proteins, P, V, W, and
C, all capable of functioning in IFN antagonism (21, 45). NiV
V and P proteins sequester STAT1 and STAT2 in the cyto-
plasm in high-molecular-weight complexes (49, 52), whereas
the W protein, which shares a common N terminus with P and
V, sequesters unphosphorylated STAT1 in the nucleus (52). As
has been speculated for NiV (52), encoding multiple IFN an-
tagonists may be associated with the high virulence of some
flaviviruses or contribute to their broad host range (both in-
vertebrate and vertebrate) by overcoming IFN responses from
multiple species.
The most outstanding question raised by the current study,
given the clear effect of the S653F mutation on NS5-mediated
IFN antagonism, is what is its role in WNV virulence? We are
currently addressing this question in the mouse model. Inter-
estingly, in a comparison of sequences from WNV strains of
high and low virulence in humans, the virulent SPU116/89
strain (WNV lineage II, isolated from a fatal infection in South
Africa) had a number of variable residues in NS5 (7). Four out
of five of these (residues 623, 635, 641, and 643) map within the
same pocket on NS5 as residue 653 (data not shown). Thus, we
speculate that this virus may have an increased capacity to
suppress IFN responses compared to its closely related but less
virulent South African strains. A greater understanding of the
precise roles of specific residues required for IFN antagonism
by WNV NS5 will shed light on their role in virulence and
could be exploited in the development of live attenuated vac-
cines or antiviral therapeutics.
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